Andy Tran
Principal at Matrix Capital Management
Greater Boston
Overview
Work Experience
Board Observer and Investor
2022 - Current
Board Director and Lead Investor
2022
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Raised $496,000,000.00 from Logos Capital, Frazier Life Sciences, Janus Henderson Investors and Deep Track Capital.
Board Director and Lead Investor
2021
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
Raised $177,000,000.00 from JDRF T1D Fund, Novartis Venture Fund, RA Capital Management, Avidity Partners, Seattle Children’s, Matrix Capital Management and OrbiMed.
Principal
2021
Leading investments in innovative biotechnology and healthcare companies. Focusing on long term investing out of a $8Bn AUM hedge fund to support companies through their entire life cycle (from early through crossover and public stages).
Investment Partner
2018 - 2021
Investing in early stage ventures at the frontier of biotech and engineering in therapeutics, diagnostics and tools. Seed and Series A Lead investments include Scribe Therapeutics, Insitro, Genesis Therapeutics, EQRx, Octant Biosciences, Tmunity, Nautilus, Earli, and several stealth seeds in the biotech space.
Andreessen Horowitz is a stage-agnostic venture capital firm with assets under management across multiple funds.
Investor and Board Observer
2018 - 2021
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.
Raised $120,000,000.00 from Prevail Therapeutics.
Board Observer
2018 - 2021
Investor
2018 - 2021
Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
Raised $643,000,000.00 from Alexandria Venture Investments, BlackRock, HOF Capital, CPP Investments, Google Ventures, Foresite Capital, Casdin Capital, Temasek Holdings, T. Rowe Price and Third Rock Ventures.
Investor
2018 - 2021
Board Observer
2018 - 2021
Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Raised $1,351,550,000.00 from BrightEdge Fund, T. Rowe Price, ArrowMark Partners, Roche, Section 32, Sands Capital Ventures, Artis Ventures (AV), Andreessen Horowitz, ARK Investment Management and Pura Vida Investments.